Novel Pyridine Compounds
US-2024316020-A1 · Sep 26, 2024 · US
US8969574B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8969574-B2 |
| Application number | US-201414250009-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 10, 2014 |
| Priority date | Apr 7, 2010 |
| Publication date | Mar 3, 2015 |
| Grant date | Mar 3, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a substantially a solid form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1, Solvate Form A and Compound 1, HCl Salt Form A), processes for making such forms, pharmaceutical compositions thereof, and methods of treatment therewith.
Opening claim text (preview).
We claim: 1. A method of treating a CFTR mediated disease is selected from the group consisting of COPD, osteoporosis, emphysema, dry-eye disease, male infertility, and pancreatic insufficiency in a mammal comprising administering to the mammal an effective amount of 3-(6 (1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1), HCl Salt Form A, or a pharmaceutical composition comprising 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxo…
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.